Literature DB >> 19458127

Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice.

Tomoki Kosugi1, Takahiro Nakayama, Marcelo Heinig, Li Zhang, Yukio Yuzawa, Laura Gabriela Sanchez-Lozada, Carlos Roncal, Richard J Johnson, Takahiko Nakagawa.   

Abstract

Hyperuricemia has recently been recognized to be a risk factor for nephropathy in the diabetic subject. We tested the hypothesis that lowering uric acid with a xanthine oxidase inhibitor might reduce renal injury in the diabetic mouse. Diabetic (db/db) mice were treated with allopurinol or no treatment for 8 wk. Serum uric acid, renal function, and histology were assessed at death. The direct effect of uric acid in human proximal tubular epithelial cells was also evaluated under normal or high glucose condition. We found that db/db mice developed hyperuricemia, albuminuria, mesangial matrix expansion, and mild tubulointerstitial disease. Allopurinol treatment significantly lowered uric acid levels, reduced albuminuria, and ameliorated tubulointerstitial injury, but it did not prevent mesangial expansion. The mechanism for protection was shown to be due to a reduction in inflammatory cells mediated by a reduction in ICAM-1 expression by tubular epithelial cells. Interestingly, allopurinol did not reduce oxidative stress in the kidney. An inflammatory role of uric acid on tubular cells was also confirmed by our in vitro evidence that uric acid directly induced ICAM-1 expression in the human proximal tubular cell. In conclusion, hyperuricemia has a pathogenic role in the mild tubulointerstitial injury associated with diabetic nephropathy but not glomerular damage in db/db mice. Lowering uric acid may reduce tubulointerstitial injury in diabetes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458127      PMCID: PMC2724243          DOI: 10.1152/ajprenal.00092.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  35 in total

Review 1.  Leukocyte recruitment and vascular injury in diabetic nephropathy.

Authors:  Elena Galkina; Klaus Ley
Journal:  J Am Soc Nephrol       Date:  2006-01-04       Impact factor: 10.121

2.  Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.

Authors:  Takahiko Nakagawa; Waichi Sato; Olena Glushakova; Marcelo Heinig; Tracy Clarke; Martha Campbell-Thompson; Yukio Yuzawa; Mark A Atkinson; Richard J Johnson; Byron Croker
Journal:  J Am Soc Nephrol       Date:  2007-01-03       Impact factor: 10.121

Review 3.  Significance of tubulointerstitial changes in diabetic renal disease.

Authors:  F N Ziyadeh
Journal:  Kidney Int Suppl       Date:  1996-05       Impact factor: 10.545

4.  Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol.

Authors:  Marí-Carmen Desco; Miguel Asensi; Rafael Márquez; José Martínez-Valls; Máximo Vento; Federico V Pallardó; Juan Sastre; José Viña
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism.

Authors:  Marilda Mazzali; John Kanellis; Lin Han; Lili Feng; Yi-Yang Xia; Qiang Chen; Duk-Hee Kang; Katherine L Gordon; Susumu Watanabe; Takahiko Nakagawa; Hui Y Lan; Richard J Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2002-06

6.  Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.

Authors:  F N Ziyadeh; B B Hoffman; D C Han; M C Iglesias-De La Cruz; S W Hong; M Isono; S Chen; T A McGowan; K Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial.

Authors:  Mojgan Afshari; Bagher Larijani; Ali Rezaie; Alireza Mojtahedi; Mohammad Jafar Zamani; Fatemeh Astanehi-Asghari; Sara Mostafalou; Arash Hosseinnezhad; Ramin Heshmat; Mohammad Abdollahi
Journal:  Biomed Pharmacother       Date:  2004-12       Impact factor: 6.529

8.  Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.

Authors:  Tomoki Kosugi; Yukio Yuzawa; Waichi Sato; Hanayo Kawai; Seiichi Matsuo; Yoshifumi Takei; Takashi Muramatsu; Kenji Kadomatsu
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

9.  Thiazide diuretics exacerbate fructose-induced metabolic syndrome.

Authors:  Sirirat Reungjui; Carlos A Roncal; Wei Mu; Titte R Srinivas; Dhavee Sirivongs; Richard J Johnson; Takahiko Nakagawa
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

10.  Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.

Authors:  M Fujii; T Inoguchi; Y Maeda; S Sasaki; F Sawada; R Saito; K Kobayashi; H Sumimoto; R Takayanagi
Journal:  Kidney Int       Date:  2007-06-13       Impact factor: 10.612

View more
  70 in total

Review 1.  Oxidative stress in diabetic nephropathy.

Authors:  N Kashihara; Y Haruna; V K Kondeti; Y S Kanwar
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Uric acid as a mediator of diabetic nephropathy.

Authors:  Diana I Jalal; David M Maahs; Peter Hovind; Takahiko Nakagawa
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

Review 3.  Fructose and uric acid in diabetic nephropathy.

Authors:  Petter Bjornstad; Miguel A Lanaspa; Takuji Ishimoto; Tomoki Kosugi; Shinji Kume; Diana Jalal; David M Maahs; Janet K Snell-Bergeon; Richard J Johnson; Takahiko Nakagawa
Journal:  Diabetologia       Date:  2015-06-07       Impact factor: 10.122

4.  Improved renal function in diabetic patients with acute gout treated with anakinra.

Authors:  Gowrie Balasubramaniam; Michael Almond; Bhaskar Dasgupta
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

Review 5.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

Review 6.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

Review 7.  Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors:  Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2018-02-27       Impact factor: 8.860

Review 8.  Does Altered Uric Acid Metabolism Contribute to Diabetic Kidney Disease Pathophysiology?

Authors:  Ambreen Gul; Philip Zager
Journal:  Curr Diab Rep       Date:  2018-03-01       Impact factor: 4.810

9.  Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.

Authors:  Seiji Itano; Hiroyuki Kadoya; Minoru Satoh; Takashi Nakamura; Takayo Murase; Tamaki Sasaki; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-21

10.  Fructose tolerance test in obese people with and without type 2 diabetes.

Authors:  Ebaa Al-Ozairi; Christopher J Rivard; Laura Gabriela Sanchez Lozada; Miguel A Lanaspa; Petter Bjornstad; Danah Al Salem; Asma Alhubail; Amira Megahed; Masanari Kuwabara; Richard J Johnson; Reem A Asad
Journal:  J Diabetes       Date:  2019-09-18       Impact factor: 4.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.